annualized clinical fracture rate

Biomarker

Related News

Class Action Lawsuits Filed Against Atara, Ultragenyx, Mereo, and Vistagen Over Alleged Misstatements

Mar 28, 2026

Class action lawsuits allege false statements about clinical trial results and regulatory prospects at Atara Biotherapeutics, Ultragenyx, Mereo BioPharma, and Vistagen Therapeutics. The complaints cite failed Phase 3 studies for setrusumab in Osteogenesis Imperfecta and fasedienol for social anxiety disorder, along with manufacturing issues affecting Atara's tabelecleucel application. Investors have deadlines ranging from April to May 2026 to seek lead plaintiff status.

Opus Genetics Reports Progress in Gene Therapy Pipeline; Ultragenyx Announces Restructuring

Mar 10, 2026

Opus Genetics reported positive early data from its BEST1 gene therapy program and expects FDA action on its presbyopia treatment in October 2026. Ultragenyx announced 2025 revenue of $673 million and initiated a strategic restructuring plan targeting profitability in 2027.

Ultragenyx Faces Securities Class Action After Phase 3 Setrusumab Trial Failures

Dec 30, 2025

Ultragenyx Pharmaceutical faces federal securities class action lawsuits following the failure of Phase 3 Orbit and Cosmic studies for setrusumab in Osteogenesis Imperfecta, with stock falling over 42% after December 2025 results announcement.